Transportation Systems: The Outlook for Reauthorization of the

Pier Paolo Claudio, M.D., Ph.D.

July 2009

CURRICULUM VITAEPier Paolo Claudio

PERSONAL DATA:

Date and Place of Birth: May 20, 1964; Naples, Italy.

Laboratory Telephone No.: (304) 696-3576

Office Telephone No.: (304) 696-3516

Laboratory address: Joan C. Edwards School of Medicine,

Marshall University,

Robert C. Byrd Biotechnology Science Center,

One John Marshall Drive,

Dept. of Biochemistry and Microbiology,

& Department of Surgery,

Suite 336Q,

Huntington, WV 25755

E-mail : [email protected]

Private E-mai: [email protected]


EDUCATION:

1983-1989 M.D. Degree, summa cum laude. Medical School,University of Naples “Federico II”, Naples, Italy.

1989-1994 Residency program and Ph.D. in Maxillo-Facial Sciences. Medical School,University of Naples “Federico II”, Naples, Italy.

PROFESSIONAL EXPERIENCE:

1985-1989 Internship at Dept. of Maxillo-Facial Surgery,Medical School, University of Naples “Federico II”, Naples, Italy.

1989-1994 Residency program and Ph.D. in Maxillo-Facial Sciences, Medical School,University of Naples “Federico II”, Naples, Italy.

1992 Research fellow of the Sloan Kettering Cancer Center, Head andNeck Department, New York, USA.

1993-1994 Research fellow of the Fels Institute for CancerResearch and Molecular Biology.Temple University, School of Medicine, Philadelphia,PA 19140.

1994 - 1996 Post-doctoral fellow of the Jefferson Cancer Institute,Thomas Jefferson University, Philadelphia, PA 19107.

1996-1998 Instructor, Dept. of Pathology, Anatomy and Cell Biology, Thomas JeffersonUniversity, Philadelphia, PA 19107

1998-2002 Assistant Professor, Dept. of Pathology, Anatomy and Cell Biology, ThomasJefferson University, Philadelphia, PA 19107

1997-1998 Scientific collaboration contract with the University of Naples“Federico II,” Italy.

1998- 2004 Assistant Professor, Dept. of Odontostomatologic and Maxillofacial Sciences,Medical School, University of Naples “Federico II”, Naples, Italy.

2004- 2006 Associate Professor, Dept. of Biology, Center for Biotechnology,Temple University, Philadelphia, PA 19122.

2004- 2006 Director of Molecular Therapeutics Program,Center for Biotechnology,Temple University, Philadelphia, PA 19122.

2006- present Associate Professor, Dept. of Biochemistry and Microbiology,Joan C. Edwards School of Medicine,Marshall University, Huntington, WV 25705.

2006- present Associate Professor, Dept. of Surgery,Joan C. Edwards School of Medicine,Marshall University, Huntington, WV 25705.

2008-present President and Founder, Phoenix Biotherapeutics, LLC

AWARDS:

1987 II Edition of the national award for young researchers“A. Schweitzer”, Italy.

1989 M.D. Degree, Summa cum laude.1994 Residency program in Maxillo-Facial Surgery, Summa cum laude.1999 Lions Club Napoli-Mergellina for outstanding achievements in cancer research.2002 Who’s Who in Science and Engineering, 2002 edition.2003 Who’s Who in Science and Engineering, 2003 edition


2003 2000 Outstanding Scientists of the 21st Century.2004 Who’s Who in Science and Engineering, 2004 edition2004 Research Board of Advisors, Who’s is Who.2004 Rotary Club – Napoli for outstanding achievements in gene therapy2007 International Award “Sebetia-Ter” for Biomedical Sciences2008 Lion’s Club Fondi for Stem Cell Research

FELLOWSHIPS:

1989-1994 Fellowship awarded for training in Maxillo-Facial Surgery at theDepartment of Maxillo-Facial Surgery, University of Naples“Federico II,” Italy.

1994-1995 Fellowship from “Lega Nazionale Lotta contro i Tumori” of theNational Institute of Tumor “Fondazione Senatore Pascale,”Naples, Italy.

1995-1997 Fellowship from the American-Italian Cancer Foundation, New York, USA.1999-2001 Fellowship from the “Associazione Leonardo di Capua”, Napoli, Italy,

for a research project on Nasopharyngeal Cancer.

GRANTS:

PastWW Smith Charity Foundation. # C0305Pier Paolo Claudio (PI): Ultrasound enhancement of viral-mediated gene transfer following systemicadministration. $ 120,000 (Expired Nov, 2006)

NIH R01 CA60999: Rb2/p130 from the mechanism to gene therapy.Pier Paolo Claudio (CoPI) $ 1,250,000

NIH P01 NS36466-08: Project #2 Tumor suppressor Rb family/pRb2 in medulloblastoma.Pier Paolo Claudio (CoPI) $ 750,000 Project#2

CDDC grant: Microgravity sensitization to chemotherapy of multi-drug resistant cancer cellsPier Paolo Claudio (PI) $ 20,000/year

CurrentNIH R21 CA131395 Ultrasound guided site-specific gene delivery in prostate cancerPier Paolo Claudio (PI) $ 385,000

NIH R03: Image guided enhancement of mda-7 gene therapy in pancreas adenocarcinomaPier Paolo Claudio (PI) $100,000

Pending:NIH R15: Cdk9 and p53 interplay in oral cancerPier Paolo Claudio (PI) $ 150,000

NIH R01: Image guided enhancement of mda-7 gene therapyPier Paolo Claudio (PI) $1,250,000


MENTORING EXPERIENCE Primary mentor for Alessandra Zamparelli, Master student at Jefferson University (1998-2002). Primary mentor for Chiara Mariano, Ph.D. student at Temple University (2002-2005) Primary mentor for Tiziana Tonini, Ph.D. student at Temple University (2002-2005) Primary mentor for Giovanni Abbadessa, Ph.D. student at Temple University (2002-2005) Secondary mentor for Steven Tutton, Ph.D. student at Temple University (2002-2006) Secondary mentor for Giuseppe Russo, Ph.D. student at Temple University (2002-2006). Primary mentor for Viviana Vogiatzi, Ph.D. student at Temple University (2002-2006). Primary mentor for Sarah Elizabeth Daron Kelly, a Master student in my laboratory at Marshall

University (2006-2009) Secondary mentor for Joseph Adam Hall, Ph.D. student in Dr. Philippe Georgel’s laboratory at

Marshall University (2007-present). Primary mentor for Ms. Miranda Carper, Ph.D. student in my laboratory at Marshall University

(2007-present). Primary mentor for Mr. Rounak Nande, Master student in my laboratory at Marshall University

(2008-present) Primary mentor for Sarah Elizabeth Daron Kelly, a Ph.D. student in my laboratory at Marshall

University (2009- )

UNIVERSITY SERVICES:

2006-present Member of Marshall University Library Committee

2007-present Member of the Marshall University Institutional Biosafety Committee (IBC)

2008-present Member of the Marshall University Faculty Senate

ORGANIZATION AFFILIATIONS:

Since 1990 Societa’ italiana dei Giovani Chirurghi (S.P.I.G.C.)Since 1990 Societa' Italiana di Chirurgia Maxillo Facciale (S.I.C.M.F.)Since 1991 European Association for Cranio-Maxillo-Facial Surgery (E.A.C.M.F.)Since 2000 American Association for Cancer Reserach (AACR)Since 2008 President and Founder of the Green Hope Foundation for Cancer

Research and Molecular Medicine.Since 2009 American Society for Gene & Cell Therapy. (ASGCT)Since 2009 Head & Neck Optical Diagnostics Society (HNODS)

GRANTS EVALUATOR BOARD:

1999 – 2003 Expert-Evaluator of the European Commission for the V FrameworkProgram (Science, Research and Development)

2000-present Grant evaluator for the Department of Veteran Affairs. Livermore, CA.2004-present Ad Hoc Grant evaluator NIH, Bethesda, MD2008-present Grant evaluator EVAL-INCO (Evaluators Database for International Cooperation)


JOURNAL REVIEWER:

From 1997 Cancer ResearchFrom 1999 Journal of Viral ImmunologyFrom 1999 Journal of NeuroimmunologyFrom 1999 Journal of VirologyFrom 2000 Human PathologyFrom 2000 Life SciencesFrom 2000 Clinical Cancer ResearchFrom 2000 J Cell PhysiologyFrom 2000 J Biol ChemistryFrom 2000 OncogeneFrom 2001 Int. J. of CancerFrom 2002 American Journal of Cardiovascular ResearchFrom 2003 PNASFrom 2004 Journal of Experimental & Clinical Cancer ResearchFrom 2005 Journal of UrologyFrom 2005 Digestive Disease and SciencesFrom 2006 NeoplasiaFrom 2007 Molecular TherapyFrom 2008 Brain Research

JOURNAL EDITOR:

2001- The women’s oncology review (Assistant and contributing Editor)2004- Regional Editor of the Journal of Experimental & Clinical Cancer Research (Editor-USA)2005- International Journal of Biomedical Science (Molecular Biology Section)2005- Drugs News and Perspectives (Editor-USA)2005- Drugs of Today (Editor USA)2005- Drugs of the Future (Editor USA).2006- Journal Experimental & Clinical Cancer Research (Editor-USA)2008 Current Signal Transduction Therapy (Editor-USA)


PATENTS:

Awarded:1. US Patent Application Number 6596698. Methods of inhibiting smooth muscle cellproliferation and preventing restenosis with a vector expressing RB2/p130. Issued onJuly 22, 2003.2. U.S. Patent Application Serial Number 10/250,805 “Method for quantification ofrecombinant viruses” issued on February 12, 2004.

Pending:1. European Patent Application. Methods of inhibiting smooth muscle cell proliferationand preventing restenosis with a vector expressing RB2/p130.2. European Patent Application “Method for quantification of recombinant viruses”3. Japanese Patent Application. Methods of inhibiting smooth muscle cell proliferationand preventing restenosis with a vector expressing RB2/p130.4. Japanese Patent Application “Method for quantification of recombinant viruses”5. U.S. Provisional Patent Application “Osteointegrated implant system”6. Italian Patent Application: “Osteointegrated implant”7. U.S. Patent Application “Method and composition for the site-selective gene delivery using viruses”8. U.S. Provisional Patent Application “Stem Cell and Associated Factor Production Method” 9. U.S. Provisional Patent Application “Methods for stem cells production and therapy”10. U.S. Provisional patent Applicartion “Methods and composition for site-selective Mda-7/IL24 genedelivery”


TALKS:

1. Claudio P.P. (1992): L’impiego del Laser C02 nella chirurgia del cavo orale.

2. (Surgical use of the CO2 Laser in the oral cavity) IV giornate mediterranee di odontoiatria.Napoli

3. Claudio P.P.(1992): I reinterventi nel cancro differenziato della tiroide.

4. (Interventions for recurrence on differentiated cancers of the thyroid) V Cong. Naz. S.P.I.G.C.Ischia, May 21-23.

5. Pier Paolo Claudio (1999): Rb2/p130 in the cell cycle and tumorigenesis. Relazione allasessione “Cell Cycle and Growth Control” del Meeting annuale della German Society for CellBiology (DGZ), Rostock, Germany, March 14-18.

6. Claudio P.P. (1999): Anno 2000. I geni: bersagli nella diagnosi e nella terapia del cancro. (Year2000. Genes: targets in the diagnosis and therapy of cancer). Presidio Ospedaliero Dono Svizzero,Premio Lions Club, Napoli Mergellina, distretto 108YA. Formia, Italy, October 20.

7. Claudio P.P. (2000): Ruolo dei geni oncosoppressori nella terapia delle neoplasie. Prospettive nelcarcinoma della prostata. (Role of oncosuppressor genes in neoplasias therapy. Perpectives inprostate cancer). Istituto nazionale per lo Studio e la Cura dei Tumori, Fondazione SenatorePascale, Napoli, Italy, May 9.

8. Claudio P.P. (2000): Mutations in the Retinoblastoma-related gene RB2/p130 in primarynasopharyngeal carcinoma. International Conference on Basic and Clinical Aspects of Cell CycleControl, Siena, Italy, May 31.

9. Claudio P. P. (2000): Mutations in the Retinoblastoma-related gene RB2/p130 in primarynasopharyngeal carcinoma. Napoli, 24-27 Settembre.

10. Claudio P. P. (2000): Oncosuppressor genes as molecular target for neoplasias gene therapy. Firstinternational Congress on new molecular target for neoplasias therapy. Buenos Aires, October 7-8.

11. Claudio P. P. (2001): Ruolo della terapia genica nella cura dei tumori del polmone. Forumnazionale di Oncologia (SIT), Foggia, 29-31 marzo.

12. Claudio P. P. (2001): Ruolo della biologia molecolare nella cura dei carcinomi del pancreas.Bari, 6-7 aprile.

13. Claudio P.P. (2001): Malignant Mesothelioma – Therapeutic Options and Role of SV40: AnUpdate. April 20 – 21, Chicago, (IL).

14. Claudio P.P. (2001): New prognostic and therapeutic molecular features in head and neck cancer.XII SICMF Congress, 6-8 June, Naples, Italy.

15. Claudio P.P. (2001): pRb2/p130 and p107 associate with the nuclear matrix and E2F4transcription factor in a cell cycle-specific manner. Aug 16, Saint Paul (VT).Claudio P.P. (2001):Molecular genetics in the pathogenesis, prognosis and therapy of gynecological malignancies. 3rdJoint International Workshop “Histologic and Cytologic Characterization of Human Tumors:Adjuncts in the Diagnosis, Prognosis and Clinical Monitoring”, October 10-13, Ischia, Italy.

16. Claudio P.P. (2002): Ruolo della biologia molecolare nei carcinomi del colon. Forum nazionaledi Oncologia (SIT), Foggia, 14-16 April.

17. Claudio PP. (2002): RB2/p130 gene enhanced expression down-regulates Vascular Epithelial


Growth Factor expression and inhibits Angiogenesis in vivo. European Respiratory Society (ERS)Annual Congress, Stockholm, 13-18 September.

18. Claudio P.P. (2003): Gene transfer delivery systems: current approaches and future perspectives.4th Joint International Workshop “Histologic and cytologic characterization of human tumors:new basic discoveries and frontiers in diagnosis, prognosis and prediction of response to therapyin human thyroid, urinary bladder and prostate tumors. Ischia, Italy, April 30-May 3.

19. Claudio P.P. Rapid Selection and Proliferation of Cancer Stem Cells in a Nasa DevelopedMicrogravity Bioreactor: Therapeutic Implications. May 27, 2008. Invited Talk to the CeingeInstitute for Biotechnology, Naples, Italy.

20. Claudio P.P. Ultrasound Mda7/IL-24 Viral-Mediated Gene Transfer In Vitro and In Vivo.University of Naples, “Federico II”, School of Medicine, May 29, 2008.

21. Claudio P.P. Rapid Selection and Proliferation of Cancer Stem Cells in a Nasa DevelopedMicrogravity Bioreactor: Therapeutic Implications. May 22, 2008. Invited Talk from the Lion’sClub, Fondi Hospital, Fondi, Italy.

22. Claudio P.P. Ultrasound Mda7/IL-24 Viral-Mediated Gene Transfer In Vitro and In Vivo.Marshall University, Johan C Edwards School of Medicine, Cancer Grand Rounds, June, 2008.


PAPERS AND COMMUNICATIONS AT CONGRESSES:

1. F. Claudio, F. Cacace, F. Scognamiglio, M. Pizzorusso, A. Amato, P.P. Claudio, F. Ionna, D. Paladino.(1984): Cavo orale: proposta di una nuova classificazione clinica.(Tumors of the oral cavity: proposal fora new clinical classification) Atti VIII Cong. Naz. S.I.C.O. Bologna, Pag. 1315 - 1317.

2. A. Iazzetta, P.P. Claudio, A. De Martino, A. Guarino, F. Ionna, O. Schiappa. (1984): La nutrizioneenterale totale in chirurgia maxillo Faciale.(Total parenteral nutrition in Maxillo-Facial surgery) Atti VIIICong. Naz. S.I.C.O. Bologna, Pag. 687 - 691. 3. F. Claudio, M. Pizzorusso, F. Ionna, P.P. Claudio, F.Cacace. (1985): I tumori avanzati differenziati della tiroide: esperienza dell'Istituto dei tumori di Napoli.(Advanced tumors of the thyroid: experience of the Cancer Institute of Naples) Atti Cong. Sez. ital.International College of Surgeons. Napoli, Pag. 223.

4. F. Claudio, F. Scognamiglio, F. Ionna, P.P. Claudio, F. Cacace, G. Savastano, L. Califano, A. Cortese.(1985): Le infusioni arteriose selettive nei Carcinomi cutanei avanzati del capo. (Selective arterialinfusions in the advanced cutaneous Carcinomas of the head) Atti IV Cong. ital. Chir. Max. Fac. Ancona,Pag. 889 - 890.

5. C. Giardino, G.S. Sica, A. Cozzolino, G. Savastano, F. Claudio, F. Cacace, G. Campobasso, P.P.Claudio. (1985): La nostra esperienza nella chirurgia ricostruttiva per i tumori del labbro. (Ourexperience in the reconstructive surgery for lips tumors) Atti IV Cong. ital. Chir. Max. Fac. Ancona, Pag.189 - 199.

6. F. Claudio, A. Amato, D. Paladino, P.P. Claudio, F. Ionna, C. Giardino, R. De Santis, M. Poltronieri.(1985): Gli interventi allargati per tumori avanzati della parotide. (Commando intervention for advancedtumors of the parotid gland) Atti IV Cong. ital. Chir. Max. Fac. Ancona, Pag. 891 - 893.

7. F. Claudio, F. Scognamiglio, P.P. Claudio, D. Paladino, G. Campobasso. (1985): Metastasi linfonodalinei tumori del cavo orale. (Lymphonodal metastasis in oral cancers) Atti IV Cong. ital. Chir. Max. Fac.Ancona, Pag. 881 - 883.

8. F. Claudio, F. Scognamiglio, M. Pizzorusso, P.P. Claudio, G. Campobasso, D. Paladino, C. Giardino,V. Minopoli, G. Vittozzi.(1985): Gli interventi allargati nei tumori avanzati della testa collo. (Commandointervention for advanced tumors of the head and neck) Atti IV Cong. ital. Chir. Max. Fac. Ancona, Pag.899 - 901.

9. F. Claudio, A. Amato, D. Paladino, P.P. Claudio, P. Marcolin, F. Ionna, C. Giardino, L. Califano.(1985): La linfadenectomia nei casi N2 - N3 per tumori del cavo orale. (Lymphoadenectomy in oralcancers with N2-N3) Atti IV Cong. ital. Chir. Max. Fac. Ancona, Pag. 495 - 497.

10. F. Claudio, F. Scognamiglio, A. Amato, D. Paladino, P.P. Claudio, G. Vela. (1985): I tumori avanzatidel cavo orale: gli interventi allargati. Esperienza dell'Istituto dei tumori di Napoli.(Advanced tumors ofthe oral cavity: commando intervention. Experience of the Cancer Institute of Naples) Atti IX Cong. Naz.S.I.C.O. S. Margherita di Pula, Pag. 881 – 884.

11. F. Claudio, M. Pizzorusso, P.P. Claudio, F. Scognamiglio, , G. Campobasso. (1985): Ruolo dellaterapia infusionale selettiva nei Carcinomi cutanei avanzati del capo: esperienza dell'Istituto dei tumori diNapoli.(Role of the selective infusional therapy in advanced cutaneous carcinoma of the head. Experienceof the Cancer Institute of Naples) Atti IX Cong. Naz. S.I.C.O. S. Margherita di Pula, Pag. 873 - 876.

12. F. Claudio, F. Scognamiglio, P.P. Claudio, F. Ionna, G. Campobasso, F. Baldassarre. (1985): IlCarcinoma cutaneo nei giovani: esperienza dell'Istituto dei tumori di Napoli. (Cutaneous carcinoma inchildhood. Experience of the Cancer Institute of Naples) Atti IX Cong. Naz. S.I.C.O. S. Margherita diPula, Pag. 515 - 519.

13. F. Claudio, F. Ionna, D. Paladino, P.P. Claudio, L. Caramazza, C. Giardino, G. Savastano, G.Lavorgna. (1985): Ruolo della chirurgia nella programmazione terapeutica dei tumori maligni avanzatidel cavo orale. (Role of surgery in advanced malignant tumors of the oral cavity) Atti XX Cong.S.I.O.C.M.F. S. Vincent, Pag. 211- 214.


14. F. Claudio, D. Paladino, P.P. Claudio, G. Campobasso, F. Ionna, C. Giardino, G.S. Sica, A.Cozzolino.(1985): Le dissezioni linfonodali nei tumori maligni del cavo orale. (Lymphonodal dissectionin malignant tumors of the oral cavity) Atti XX Cong. S.I.O.C.M.F. S. Vincent, Pag. 205 - 209.

15. F. Claudio, C. Giardino, F. Ionna, P.P. Claudio, R. De Santis. (1986): Parotid advanced tumors. AttiVIII Cong. Europ. E.A.C.M.F.S. Madrid, Pag. 5.

16. F. Claudio, A. Amato, F. Cacace, F. Ionna, P.P. Claudio e M. Pizzorusso. (1987): Nuova strategiainterdisciplinare in rapporto a problemi exeretico ricostruttivi per tumori avanzati del capo e del collo.(New interdisciplinary strategy regarding ablationreconstructive problems for advanced tumors of thehead and neck) Atti XI Cong Naz. S.I.C.O. Genova, Pag. 675 - 678.

17. F. Claudio, F. Cacace, F. Ionna e P.P. Claudio. (1988): La chemioterapia infusionale selettiva neicarcinomi avanzati del capo. (Selective infusional chemotherapy in advanced carcinomas of the head)Atti XII Cong. Naz. S.I.C.O. Isola Capo Rizzuto, Pag.121 - 128.

18. F. Claudio, F. Cacace e P.P. Claudio. (1989): Linfadenectomie di principio? (Lymphoadenectomy: isit mandatory?) Atti XIII Cong. S.I.C.O. Roma, Pag. 71 - 80.

19. L. Califano, A. Cortese e P.P. Claudio. (1989): L'alimentazione artificiale in chirurgia maxillofacciale. (Artificial nutrition in maxillo-facial surgery) Atti Tavola Rotonda S.P.I.G.C., 91° Cong. S.I.C.O.Genova, Pag. 69 - 73.

20. F. Claudio, A. Amato e P.P. Claudio. (1990): Gli interventi allargati nei tumori avanzati dellaparotide. (Commando intervention in advanced tumors of the parotid gland), Atti X Cong. S.I.E.C., S.Margherita di Pula, Pag. 245 - 250.

21. P.P. Claudio, A. Amato, G. Savastano e G. Della Pietra. (1991): Le ricostruzioni con lembi cutanei emiocutanei dopo interventi demolitivi della testa-collo. (Reconstructions with cutaneous andmusculocutaneous flaps after demolitive interventions on the head and neck) Atti VII Cong. S.I.C.M.F.Ischia, Pag. 1325 - 1329.

22. P.P. Claudio, A. Amato, G. Savastano e G. Della Pietra. (1991): Ruolo della terapia chirurgica neitumori maligni avanzati della parotide. (Role of surgical therapy in malignant advanced tumors of theparotid gland) Atti VII Cong. S.I.C.M.F. Ischia, Pag. 345 - 348.

23. F. Claudio, A. Amato e P.P. Claudio. (1991): Parotidectomie: esperienza dell'Istituto dei Tumori diNapoli dal 1960 al 1988. (Parotidectomy: experience of the Cancer Institute of Naples from 1960 to1988), Atti VII Cong. S.I.C.M.F. Ischia, Pag. 213 - 220.

24. A. Amato, P.P. Claudio, G. Savastano e G. Della Pietra. (1991): La dissezione linfonodale nei tumorimaligni avanzati della parotide. (Lymphonodal dissection in malignant advanced tumors of the parotidgland), Atti VII Cong. S.I.C.M.F. Ischia, Pag. 341 - 343.

25. C. Giardino, P.P. Claudio, A. Amato e G. Savastano. (1991): Scialectomia totale versus subtotalenell'adenoma pleomorfo della parotide. (Total scialectomy versus subtotal in the pleomorphic adenoma ofthe parotid gland), Atti VII Cong. S.I.C.M.F. Ischia, Pag. 335 - 339.

26. C. Giardino, P.P. Claudio, A. Amato e G. Savastano. (1991): Tumori del cavo orale. Disseminazionelinfatica: prevenzione chirurgica. (Tumors of the oral cavity. Lymphatic spread: surgical prevention), AttiVII Cong. S.I.C.M.F. Ischia, Pag. 1161 - 1165.

27. G. Savastano, A. Russo, P.P. Claudio, G. Della Pietra, S. Siciliano. (1991): Considerazioni clinico-terapeutiche sui Carcinomi adenoideo-cistici delle ghiandole

salivari maggiori. (Clinical-therapeutic considerations on adenoid-cystic carcinomas of the major salivaryglands), Atti VII Cong. S.I.C.M.F. Ischia, Pag. 329 - 333

28. Claudio P.P., Papa F., Cangiano G. (1992): L’impiego del Laser C02 nella chirurgia del cavo orale.(Surgical use of the CO2 Laser in the oral cavity) Atti delle IV giornate mediterranee di odontoiatria.Napoli.


29. Claudio P.P., Amato A.(1992): I reinterventi nel cancro differenziato della tiroide. (Interventions forrecurrence on differentiated cancers of the thyroid) Relazione al V Cong. Naz. S.P.I.G.C. Ischia 21 - 23May, Pag. 558 - 565.

30. De Luca A., Claudio P.P., Peschle C., Giordano A., Condorelli G. (1994): Interaction between cell-cycle regulatory genes and transcription factors during skeletal muscle cell differentiation. 4thInternational Symposium on Endocrinology Under 35. Rome, Italy, 25-27 May. Advances inEndocrinology: Cell Cycle and Cancer. Ares Serono Symposia Publications (Raven Press) Pag. 37.

31. Mayol X., Baldi A., Sang N., Fu Y., De Luca A., Claudio P.P., Grana X., and Giordano A. (1994):The Adenovirus E1A oncoprotein: a link between transformation and cell cycle. 4th InternationalSymposium on Endocrinology Under 35. Rome, Italy, 25-27 May. Advances in Endocrinology: CellCycle and Cancer. Ares Serono Symposia Publications (Raven Press) Pag. 40.

32. Giordano A., Baldi A., Claudio P.P., De Luca A., Mensorio C. (1994): Adenovirus E1A targets keyregulators of cell proliferation. IIL Congresso Nazionale della Societa’ italiana di Anatomia. Roma, 2-5October.

33. De Luca A., Claudio P.P., De Luca B., Giordano A., Condorelli G.(1994): Muscle specifictranscription factors interact with cell-cycle regulatory genes during skeletal muscle cell differentiation.IIL Congresso Nazionale della Societa’ italiana di Anatomia. Roma, 2 -5 October.

34. Claudio P.P., Howard C.M., Baldi A., De Luca A., Sang N., MacLachlan T., Yuan W., Fu Y.,Condorelli G. and Giordano A. (1995): p130/RB2 has similar yet distinctive growth suppressiveproperties as retinoblastoma family members, pRb and p107. 86th Annual Meeting of the “AmericanAssociation for Cancer Research”, March 18-22. Toronto, Ontario, Canada.

35. Claudio P.P., Howard C.M., Baldi A., De Luca A., Pertile P., Condorelli G., Giordano A. (1995):Growth suppressive properties of p130/pRb2 and its subcellular localization. XXVI Congresso nazionaledella Societa’ italiana di Istochimica. 8-11 June, Napoli.

36. Baldi A., Claudio P.P., De Luca A., Giordano A. (1995): Genomic structure andimmunohistochemical pattern of the human Rb2/p130 gene in tumors. XXVI Congresso nazionale dellaSocieta’ italiana di Istochimica. 8-11 June, Napoli.

37. De Luca A., Shu L., MacLachlan T., Sang N, Claudio PP., Baldi A., Giordano A. (1995): Pitalre andPisslre, two novel cdc-2 related kinases. XXVI Congresso nazionale della Societa’ italiana di Istochimica.8-11 June, Napoli.

38. Sang N., Condorelli G., Maclachlan T., Claudio P.P., De Luca A., Yuan W., Fu Y., and Giordano A.(1995): A novel transactivation activity of adenoviral E1A oncoproteins and its involvement in regulationof host genes. The 6th SCBA (Society of Chinese Bioscientists in America) International Symposium. 24-29 June, Vancouver. Canada.

39. Claudio P.P., Baldi A., Howard C.M., MacLachalan T., and Giordano A. (1995): The pRb2/p130protein exhibits growth suppressive properties in a cell cycle dependent manner. The Imperial CancerResearch Fund, Tumour Virus Meeting on Papovaviruses, Papillomavirus and Adenoviruses. 17-22 July,1995. Churchill College, Cambridge, England.

40. Baldi A., Boccia V., Esposito V., De Luca A., Claudio P.P., MacLachlan T., Giordano A. (1996):Genomic structure and immunohistochemical pattern of the human retinoblastoma-related RB2/p130gene in normal tissues. “Cancer and the cell cycle”. Lausanne, January 17-20.

41. Shu L., MacLachlan T.K., Baldi A., De Luca A., Claudio P.P., Condorelli G., Giordano A. (1996):The PITALRE and PISSLRE cdc2-related kinases are involved in regulation of the cell cycle. “Cancerand the Cell Cycle”. Lausanne, January 17-20.

42. Claudio P.P., Baldi A., Bonetto F., Howard C.M., Raschella’ G., Giordano A., Paggi M.G. (1996):The Rb2/p130 protein and cell cycle regulation. “Cancer and the Cell Cycle”. Lausanne, January 17-20.


43. Pier Paolo Claudio and Antonio Giordano (1999): Rb2/p130 in the cell cycle and

tumorigenesis. Relazione alla sessione “Cell Cycle and Growth Control” del Meeting annuale dellaGerman Society for Cell Biology (DGZ), Rostock, March 14-18.

44. Pier Paolo Claudio, Candace M. Howard, Giulia De Falco, Luigi Fratta, Giorgio Stassi, Shin-ichiroNumata, Carmen Pacilio, Alan Davis, James M. Wilson, Massimo Volpe, Bruno Trimarco, AntonioGiordano e Gianluigi Condorelli (1999): Adenoviral RB2/p130 gene transfer inhibits smooth muscle cellproliferation and prevents restenosis following angioplasty. Philadelphia, 90th Annual Meeting A.A.C.R.,April 10-14.

45. Giulia De Falco, Luigi Bagella, Pier Paolo Claudio, Bruna Pucci, Arturo Sala and Antonio Giordano(1999): Interaction between CDK9 and B-Myb down-regulates BMyb transactivating activity. .Philadelphia, 90th Annual Meeting A.A.C.R., April 10-14.

46. .Pier Paolo Claudio, Candace M. Howard, Giulia De Falco, Carmen Pacilio, Caterina Cinti, GaetanoRomano, Corrado Minimo, Nadir M. Maraldi, John D. Minna, Larry Gelbert, Giovan Giacomo Giordanoand Antonio Giordano (1999): Mutations in the Retinoblastoma-related gene RB2/p130 in primary lungtumors and suppression of tumor growth in vivo by retroviral-mediated gene transfer. Philadelphia, 90thAnnual Meeting A.A.C.R., April 10-14.

47. Claudio P.P., Howard C., Califano L., Cinti C., Giordano A., Giardino C. Mutazioni nel geneRB2/p130, della famiglia del gene Retinoblastoma, in carcinomi primari del nasofaringe. Atti VI GiornateScientifiche delle Facolta’ di Medicina e Chirurgia, Farmacia, Medicina Veterinaria e Agraria. 17/19Maggio 2000, Napoli

48. Claudio P.P., Zupi A., Bellan C., Zamparelli A., Giordano A., Giardino C. Analisiimmunoistochimica di pRb2/p130, p107, E2F4 e pCNA nei tumori delle ghiandole salivari. Evidenza diun loro ruolo diagnostico e prognostico. Atti VI Giornate Scientifiche delle Facolta’ di Medicina eChirurgia, Farmacia, Medicina Veterinaria e Agraria. 17/19 Maggio 2000, Napoli

49. Jorio F.P., Galderisi U., Piegari E., Di Bernardo G., Cipollaro M., Cascino A., Claudio P.P., GiordanoA., Melone M.A.B. Specific role of pRb2/p130 gene in neurogenesis: its overexpression inducesastrocytes but not neuronal differentiation. Abstracts of the International Conference on Basic andClinical Aspects of Cell Cycle Control, May 29- 31, 2000; Siena, Italy.

50. La Sala D., Zamparelli A., Claudio P.P., Maltarello M.C., Trimarchi C., Ognibene A., Giordano A.,Cinti C. Characterization of molecular mechanisms in a new multidrugresistant human osteosarcoma cellline (HOS DXR150). Abstracts of the International Conference on Basic and Clinical Aspects of CellCycle Control, May 29-31, 2000; Siena, Italy.

51. Cinti C., Claudio P.P., De Luca A., Cuccurese M., D’Esposito M., La Sala D., Halazonetis T.D.,Giordano A., Maraldi M.N. A serine 37 mutation associated with two missense mutations at highlyconserved regions of p53 affect pro-apoptotic genes expression inducing γ-irradiation resistance.Abstracts of the International Conference on Basic and Clinical Aspects of Cell Cycle Control, May 29-31, 2000; Siena, Italy.

52. Trimarchi C., Claudio P.P., Zini N., Stiegler P., Marinelli F., La Sala D., Maltarello M.C., OgnibeneA., Giordano A., Cinti C. pRb2/p130 and p107 associate with the nuclear matrix and E2F4 transcriptionfactor in a cell cycle-specific manner. Abstracts of the International Conference on Basic and ClinicalAspects of Cell Cycle Control, May 29-31, 2000; Siena, Italy.

53. Claudio P.P., Califano L., Zupi A., Bellan C., Zamparelli A., Cinti C., Leoncini L., Giardino C.,Giordano A. pRb2/p130 expression in salivary gland tumors. Its prognostic and diagnostic role. Abstractsof the International Conference on Basic and Clinical Aspects of Cell Cycle Control, May 29-31, 2000;Siena, Italy.

54. Claudio P.P., Howard C., Califano L., Cinti C., Leoncini L., Giardino C., Giordano A. Mutations inthe Retinoblastoma-related gene RB2/p130 in primary nasopharyngeal carcinoma. Abstracts of the


International Conference on Basic and Clinical Aspects of Cell Cycle Control, May 29-31, 2000; Siena,Italy.

55. Claudio, P.P., Califano, L., Zupi, A., Bellan, C., Zamparelli, A., Giordano, A., Giardino, C.pRb2/p130 expression in salivary gland tumors. Its diagnostic and prognostic role. XVth Congress of theEuropean Association for Cranio-Maxillofacial Surgery, September 5-9, 2000, Edinburgh, Scotland.

56. Claudio, P.P., Howard, C.M., Califano, L., Cinti, C., Giordano, A., Giardino, C. Mutations in theRetinoblastoma-related gene RB2/p130 in primary nasopharyngeal carcinoma. XVth Congress of theEuropean Association for Cranio-Maxillofacial Surgery, September 5-9, 2000, Edinburgh, Scotland.

57. Pier Paolo Claudio, Sujatha Radhakrishnan, Shou Zheng, Marcus Saunders, Chiara Mariano, KamelKhalili, Antonio Giordano, Shohreh Amini, Bassel E Sawaya. P53 decreases the phoshorylation ofpolimerase II by cdk9. A novel mechanism for inhibition of HIV-1 gene expression. 4th JointInternational Workshop “Histologic and cytologic characterization of human tumors: new basicdiscoveries and frontiers in diagnosis, prognosis and prediction of response to therapy in human thyroid,urinary bladder and prostate tumors. Ischia, Italy, April 30-May 3.

58. Tiziana Tonini, Giuseppe Russo, Candace M. Howard, Francesca Rossi, Arturo Sala, GaetanoRomano, Antonio Giordano, and Pier Paolo Claudio. B Myb down-regulates the Retinoblastoma familymember pRb2/p130 promoter. 4th Joint International Workshop “Histologic and cytologiccharacterization of human tumors: new basic discoveries and frontiers in diagnosis, prognosis andprediction of response to therapy in human thyroid, urinary bladder and prostate tumors. Ischia, Italy,April 30-May 3.

59. Candace M. Howard, Flemming Forsberg, Ji-Bin Liu, Daniel A. Merton, Corrado Minimo, PierPaolo Claudio. Using a Commercial Ultrasound Contrast Agent for Viral Mediated Gene Transfer InVitro and In Vivo. Proceedings 6th International Symposium on Therapeutic Ultrasound. 30th August -2nd September 2006 . Oxford, UK.

60.Pierpaolo Aimola, Candace M. Howard, Pier Paolo Claudio. Ultrasound contrast mediated genetherapy in prostate cancer. Cancer Therapeutics: The Road Ahead. A Nature Conference. October 8-10,2007, Palazzo dei Congressi Di Capri, Capri, Italy.

61. S. E. Kelly, Di Benedetto A., Valluri, J.V., Claudio, P.P. Rapid selection and proliferation of cancerstem cells Published in Life in Space for Life on Earth. 22 - 27 June 2008, Angers – France


PUBLICATIONS:

1. Francesco Claudio, Francesco Cacace, Michele Pizzorusso, Ornella Schiappa, Pier Paolo Claudio,Franco Ionna, Paolo Marcolin, Antonio Amato. (1983): Strategia di trattamento delle aree di drenaggiolinfonodale nei tumori del cavo orale. (Strategy of treatment for lymphonodal drenage areas in tumors ofthe oral cavity) Il medico italiano, 27: 225 - 237.

2. Califano, A. Cortese, P.P. Claudio. (1989): L'alimentazione artificiale in chirurgia maxillo facciale.(Artificial nutrition in maxillo-facial surgery) Boll. Soc. It. Chir. 10, 3: 173 - 177.

3. Claudio, F. Cacace, M. Rotondi, G. Comella, F. Coucourde, P.P. Claudio, A. M. Bevilacqua, S.Bonassi, S. Toma. (1990): La chemioterapia intra-arteriosa nei tumori avanzati dalla testa e colloeffettuata mediante una tecnica di trasposizione carotidea. (Intra-artherial chemotherapy in advancedtumors of the head and neck through a carotid surgical transposition technique) Otorinolaringologia 40:11 - 9.

4. Giardino C., Claudio P.P. (1992): Proposta di una scheda oncologica clinica per i tumori del cavoorale. (Proposal of a new clinical chart for tumors of the oral cavity) Riv. Ital. di Chir. Max. Fac., (3): 39-48.

5. Papa F., Claudio P.P., Letizia N., Maio C., Giardino C. (1992): Su di un caso di cosidetto FibromaOssificante. (Consideration on an interesting case of ossifying fibroma) Riv. Ital. di Chir. Max. Fac., (3):53 - 58.

6. Claudio F., Rotondi M., Bonassi S., Cacace F., Comella G., Coucourde F., Claudio P.P., BevilacquaA.M., Forma F., Toma S. (1992): Factors affetting response and survival in advance head and neckcancers treated with intrarterial chemotherapy. Regional Cancer Treatment 4: 180 - 187.

7. Claudio F., Rotondi M., Bonassi S., Cacace F., Comella G., Coucourde F., Claudio P.P., BevilacquaA.M., Spadini N., Toma S. (1992): I fattori prognostici nei tumori avanzati della testa e collo trattatimediante chemioterapia intra-arteriosa. (Prognostic factors in advanced tumors of the head and necktreated with intrarterial chemotherapy) Otorinolaringologia, Vol 42, (5): 273 - 282.

8. Graña X., De Luca A., Sang N., Fu Y., Claudio P.P., Rossenblatt J., Morgan D.O. and Giordano A.(1994): PITALRE, a nuclear CDC2-related protein kinase that phosphorylates the retinoblastoma proteinin vitro. Proc. Natl. Acad. Sci. USA. Vol 91, 3834-3838.

9. Graña X., Claudio P.P., De Luca A. , Sang,N., and Giordano, A. (1994): PISSLRE, a human novelCDC2-related protein kinase. Oncogene 9, 2097-2103.

10. Claudio P.P., Howard C.M., Baldi A., De Luca A., Condorelli G., Sun Y., Colburn N., Calabretta B.,Giordano A. (1994): p130/PRb2 has similar yet distinctive growth suppressive properties asretinoblastoma family members, pRb and p107. Cancer Research 54: 5556-5560.

11. Wen S.-C., Ku D.-H., De Luca A., Claudio P.P., Giordano A., and Calabretta B. (1995): ets-2regulates cdc2 kinase activity in mammalian cells: coordinated expression of cdc2 and cyclin A. Exp.Cell Res. 217, (1): 8-14.

12. Li S., MacLachlan T., De Luca A., Claudio P.P., Condorelli G.L., and Giordano A. (1995): The cdc2-related kinase, PISSLRE, is essential for cell growth and acts in G2 phase of the cell cycle. CancerResearch 55, 3992-3995.

13. De Luca A., Baldi A., Claudio P.P., Howard C.M., Campisi S., Giordano A., Condorelli G. (1995):The retinoblastoma gene and its role in cancer and differentiation. In Future Trends in Endocrinology.Ares-Serono Symposia Series- Frontiers in Endocrinology 14: 197-206.

14. Baldi A., De Luca A., Claudio P.P., Baldi F., Giordano G.C., Tommasino M., Paggi M.G. andGiordano A. (1995): The Rb2/p130 gene product is a nuclear protein whose phosphorylation is cell cycleregulated. Journal of Cellular Biochemistry 59: 402-408.

15. Claudio P.P., De Luca A., Howard C.M., Baldi A., Firpo E.J., Koff A., Paggi M.G., Giordano A.


(1996): Functional analysis of pRb2/p130 interaction with cyclins. Cancer Research 56: 2003-2008.

16. Baldi A., Boccia V., Claudio P.P., De Luca A., Giordano A.(1996): Genomic structure of the humanretinoblastoma-related Rb2/p130 gene. Proc. Natl. Acad. Sci. 93: 4629-4632.

17. Esposito V., Baldi A., De Luca A., Paciocco G., Gröger A., Sgaramella G., Claudio P.P., GiordanoG.G., Baldi F., Caputi M., Kaiser H., Giordano A. (1997): Role of PCNA in differentiating betweenmalignant mesothelioma and mesothelial hyperplasia: prognostic considerations. Anticancer Research 17:601-604.

18. Esposito V., Baldi A., De Luca A., Claudio P.P., Signoriello G., Bolognese A., Centonze P., GiordanoG.G, Caputi M., Baldi F., Giordano A. (1997): p53 immunostaining in differential diagnosis of pleuralmesothelial proliferations. Anticancer Research 17: 733-736.

19. De Luca A., Esposito V., Baldi A., Claudio P.P, Fu Y., Caputi M., Pisano M.M, Baldi F., Giordano A.(1997): The cdc2-related kinase PITALRE phosphorylates pRb exclusively on serine and is widelyexpressed in human tissues. Journal of Cellular Physiology 172: 265-273.

20. De Luca A., MacLachlan T.K., Bagella L., Dean C., Howard C.M., Claudio P.P., Baldi A., Khalili K.,Giordano A. (1997): A unique domain of pRb2/p130 acts as an inhibitor of cdk2 kinase activity. J.Biological Chemisty 272: 20971-20974.

21. Sang N., Claudio P.P, Fu Y., Horikoshi N., Graeven U., Weinmann R., Giordano A. (1997):Transforming Region of 243 R E1A contains two overlapping but distinct Transactivation Domains. DNAand Cell Biology. 16:1321-1333.

22. Papa F., Sagliocco R., Cosimo O., Russo A., Claudio P.P., Errico M., Lavorgna G. (1997):Consideration on a case of carcinoma ex pleomorphic adenoma of the parotid gland. Minerva Stomatol.46 (11): 615-620.

23. Raschella’, G., Tanno, B., Bonetto, F., Negroni, A., Claudio, P.P., Baldi, A., Amendola, R.,Calabretta, B., Giordano, A., Paggi, M. (1998): The RB-related gene Rb2/p130 in neuroblastomadifferentiation and in B-myb promoter down-regulation. Cell Death & Diff. 5: 401-407.

24. Leri A., Liu Y., Malhotra A., Li Q., Stiegler P., Claudio P.P., Giordano A., Kajstura J., Hintze H. T.,Anversa P. (1998): Pacing-induced heart failure in dogs enhances the expression of p53 and p53-dependent genes in ventricular myocytes. Circulation. 97:194-203.

25. Leri A., Claudio P.P., Li Q., Wang X., Reiss K., Wang S., Malhotra A., Kajstura J., Anversa P.(1998): Stretch mediated release of angiotensin II induces myocytes apoptosis by activating p53 thatenhances the local renin-angiotensin system and decrease the Bcl-2-to-Bax protein ratio in the cell. J.Clin. Invest. 101(7):1326-1342.

26. Ravi K.R., Weber E., McMahon M., Williams R. J., Baylin S., Mai A., Harter L. M., Dillehay L.E.,Claudio P.P., Giordano A., Nelkin D. B., Mabry M. (1998): Activated Raf-1 causes growth arrest inhuman small cell lung cancer cells. J. Clin. Invest. 101:153-159.

27. Romano G., Claudio P.P., Kaiser H.E., Giordano A. (1998): Recent advances, prospects andproblems in designing new strategies for oligonucleotide and gene delivery in therapy. In Vivo 12: 59-68.

28. Tarro G., Esposito C., Perna M., Claudio P.P., Giordano A. (1998): Immunohistochemicalcharacterization of tumor liberated particles (TLP) expression pattern in lung cancer. Anticancer Res. 18:2365-2370.

29. Howard C.M., Claudio P.P., Gallia G., Gordon J., Giordano G.G., Khalili K., Giordano A.(1998):Retinoblastoma-related protein pRb2/p130 and suppression of tumor growth in vivo. J.Nat. Cancer Inst.19: 1451-1460.

30. Mutti L., De Luca A, Claudio P.P., Carbone M., Convertino G., Giordano A. (1998): Simian Virus40-like DNA sequences and large-T antigen-retinoblastoma family protein pRb2/p130 interaction inhuman mesothelioma. Dev. Biol.Stand.: 94:47-53.


31. Pacilio C., Florio S., Crispino A., Claudio P.P., Pacilio G., Pagnini G. (1998): Modification ofmembrane fluidity and depolarization by some anthracyclines in different cell lines. Anticancer Research.18(6A):4027-4034.

32. Pupa S.M, Howard C. M., Invernizzi A. M., De Vecchi R., Giani C., Claudio P.P., Colnaghi M. I.,Giordano A., Ménard S. (1999): Ectopic expression of pRB2/p130 suppresses the tumorigenicity of theerb-2-overexpressing SKOV3 tumor cell line. Oncogene. 18(3): 651-656.

33. Leri A, Liu Y, Claudio PP, Kajstura J, Wang X, Wang S, Kang P, Malhotra A, Anversa P. Insulin-likegrowth factor-1 induces Mdm2 and down-regulates p53, attenuating the myocyte renin-angiotensinsystem and stretch-mediated apoptosis. (1999) Am J Pathol. Feb;154 (2):567-80.

34. Minimo C., Bibbo M., Claudio P.P., De Luca A., Giordano A. (1999): The role of pRb2/p130 proteinin diagnosing lung carcinoma on fine needle aspiration biopsies. Pathol Res and Pract. 195: 67-70.

35. Numata S., Claudio P.P., Giordano A., Croce C.M. (1999): Bdp: a new member of a family of DNAbinding proteins, associates with the retinoblastoma gene product.Cancer Research, 59: 3741-3747.

36. Claudio P.P., Fratta L., Stassi G., Howard C.M., Farina F., Numata S., Pacilio C., Davis A., LavitranoM., Volpe, Wilson J.M., Trimarco B., Giordano A., and Condorelli G. (1999): Adenoviral RB2/p130 genetransfer inhibits smooth muscle cell proliferation and prevents restenosis following angioplasty.Circulation Research, 85:1032-39.

37. Leoncini L., Bellan C., Claudio P.P., Lazzi S., Cevenini G., Megha T., Laurini L., Luzi P., FraternaliOrcioni G., Piccioli M., Pileri S., Giardino C., Tosi G.M., Giordano A. (1999): Retinoblastoma relatedp107 and pRb2(p130) proteins in malignant lymphomas. Distinct mechanisms of cell growth control.Clinical Cancer Research, 12: 4065-4072.

38. De Falco G., Bagella L., Claudio P.P., De Luca A., Fu Y., Calabretta B., Sala A., Giordano A. (2000):Physical interaction between CDK9 and B-Myb results in suppression of B-myb gene autoregulation.Oncogene , 19: 373-379.

39. Pagnini U., Pacilio C., Florio S., Crispino A., Claudio P.P., Giordano A., Pagnini G. (2000).Medroxyprogesterone acetate increases anthracyclines uptake in chronic lymphatic leukemia cells: role ofnitric oxide and lipid peroxidation. Anticancer Research, 20 (1A): 33-42.

40. Claudio P.P., Howard C.M., Fu Y., Califano, L., Mercer E.W., Micheli, P., Caputi, M., Giordano A.(2000): Mutations in the Retinoblastoma-related Gene RB2/p130 in primary nasopharyngeal carcinoma.Cancer Research, 60: 8-12.

41. Claudio P.P., Howard C.M., Pacilio C., Cinti C., Romano G., Minimo C., Maraldi N.M., Minna J.D.,Gelbert L., Leoncini, L., Tosi, G.M., Micheli, P., Caputi M., Giordano G.G., and Giordano A. (2000):Mutations in the Retinoblastoma-related gene RB2/p130 in lung tumors and suppression of tumor growthin vivo by retroviralmediated gene transfer. Cancer Research, 60: 372-382.

42. Cinti C., Claudio P.P., Howard C.M., Neri L.M., Fu Y., Leoncini, Tosi G.M., Maraldi N.M., GiordanoA. (2000) Genetic alterations disrupting the nuclear localization of the retinoblastoma related geneRB2/p130 in human cell lines and primary tumors. Cancer Research, 60: 383-389.

43. Caterina Cinti, Lorenzo Leoncini, Aggrey Nyongo, Filomena Ferrari, Stefano Lazzi, Cristiana Bellan,Alessandra Zamparelli, Pier Paolo Claudio, Nadir Mario Maraldi, Piero Tosi and Antonio Giordano.(2000): Genetic alterations of the retinoblastoma related gene RB2/p130 identify different pathogeneticmechanism in and among Burkitt's lymphoma subtypes. American J. of Pathology, 156 (3): 751-760.

44. Claudio P.P., Caputi M., Giordano A. (2000): The Rb2/p130 gene: the latest weapon in the waragainst lung cancer? Clin Canc. Research, 6 (3): 754-64.

45. Candace M. Howard, Pier Paolo Claudio, Antonio De Luca, Peter Stiegler, Francesco Paolo Jori,Nabile M. Safdar, Mario Caputi, Kamel Khalili, and Antonio Giordano. (2000): Inducible pRb2/p130expression and growth suppressive mechanisms: evidence of a pRb2/p130, p27Kip1, and cyclin E


negative feedback regulatory loop. Cancer Research, 60: 2737-2744.

46. Perrotti, D., Iervolino, A., Cesi, V., Cirinna, M., Lombardini, S., Grassilli, E., Bonatti, S. Claudio,P.P., Calabretta, B. (2000) BCR-ABL prevents c-jun-mediated and proteasome-dependent FUS (TLS)proteolysis through a protein kinase CbetaII dependent pathway. Mol Cell Biol. 20(16): 6159-69.

47. Claudio, P.P. (2000) Immunohistochemical investigation of new suppressor oncogene p130 in oralsquamous cell carcinoma. Oral Oncology, Letter to the Editor 36(5): 497.

48. Cinti C., Claudio P.P., Howard, C.M., Neri L.M., De Luca A., Waterman J.L.F., Azzoni L., GiordanoA., Halazonetis T.D., Maraldi N.M. (2000): A serine 37 mutation associated with two missense mutationsat highly conserved regions of p53 induces -irradiation resistance affecting pro-apoptotic genesexpression. Oncogene, 19 (44): 5098-5106.

49. Pier Paolo Claudio, Peter Stiegler, Candace M. Howard, Cristiana Bellan, Corrado Minimo, JanuszRak, Al Kovatich, Paola De Fazio, Pietro Micheli, Mario Caputi, Robert Kerbel, Giovan GiacomoGiordano, and Antonio Giordano. (2001): RB2/p130 gene enhanced expression down-regulates VascularEpithelial Growth Factor expression and inhibits Angiogenesis in vivo. Cancer Research, (62):462-68.

50. Claudio, P. P., Cinti, C., and Giordano, A. Application of the primer in situ DNA synthesis (PRINS)technique to titer recombinant virus and evaluation of the efficiency of viral transduction, Anal Biochem.291: 96-101., 2001.

51. Galderisi, U., Melone, M. A., Jori, F. P., Piegari, E., Di Bernardo, G., Cipollaro, M., Cascino, A.,Peluso, G., Claudio, P. P., and Giordano, A. pRb2/p130 gene overexpression induces astrocytedifferentiation, Mol Cell Neurosci. 17: 415-25, 2001.

52. Zini, N., Trimarchi, C., Claudio, P. P., Stiegler, P., Marinelli, F., Maltarello, M. C., La Sala, D., DeFalco, G., Russo, G., Ammirati, G., Maraldi, N. M., Giordano, A., and Cinti, C. pRb2/p130 and p107control cell growth by multiple strategies and in association with different compartments within thenucleus, J Cell Physiol. 189: 34- 44, 2001.

53. Pier Paolo Claudio, Alessandra Zamparelli, Luigi Califano,Aldo Zupi, Cristiana Bellan, CorradoMinimo, Candace M. Howard, Giovanna Carrillo, Pietro Micheli, Caterina Cinti, Lorenzo Leoncini,Costantino Giardino, Antonio Giordano. Expression of Cell-Cycle Regulated Proteins pRB2/p130, p107,E2F4, p27, and of pCNA in Salivary Gland Tumors. Prognostic and diagnostic implications. RivistaItaliana di Chirurgia Maxillo Facciale Vol XII, 1: 37-48, 2001.

54. Francesco Papa, Salvatore Ferrara, Livia Felicetta, Giovanni Lavorgna, Margherita Matarazzo,Stefania Staibano, Sabrina Troisi, and Pier Paolo Claudio. Mandibular metastatic hepatocellularcarcinoma: report of a case involving severe and uncontrollable hemorrhage. Anticancer Res. 21: 2121-30., 2001.

55. Pier Paolo Claudio. Asian-American variants of human papillomavirus 16 and risk for cervicalcancer: a case control study. J Natl Cancer Inst 2001; 93: 1325-1330. Commentary Basic Sciences, TheWomen’s Oncology Review, 4: 357-358, 2001.

56. Claudio, P. P., Zamparelli, A., Garcia, F. U., Claudio, L., Ammirati, G., Farina, A., Bovicelli, A.,Russo, G., Giordano, G. G., McGinnis, D. E., Giordano, A., and Cardi, G. Expression of Cell-Cycle-regulated Proteins pRb2/p130, p107, p27(kip1), p53, mdm-2, and Ki-67 (MIB-1) in Prostatic GlandAdenocarcinoma, Clin Cancer Res. 8: 1808-15., 2002.

57. Pucci, B., Claudio, P.P., Masciullo, V., Bellincampi, L., Terrioni, A., Khalili, K., Melino, G.,Giordano, A. pRb2/p130 promotes radiation-induced cell death in the glioblastoma cell line HJC12 byp73 up-regulation and Bcl2 down-regulation. Oncogene 21: 5897-5905, 2002.

58. Condorelli, G.L., Morisco, C., Latronico, M., Claudio, P.P., Dent, P., Tsichlis, P., Condorelli, G.,Frati, G., Drusco, A., Croce, C.M., and Napoli C. TNF-α signal transduction in rat neonatal cardiacmyocytes: definition of pathways generating from the TNF-α receptor. FASEB, 16: 1732-37, 2002.


59. Tonini, T., Hillson, C. and Claudio, P.P. Interview with the retinoblastoma family members: do theyhelp each other? J. Cell Physiol. 192, 2: 138-150, 2002.

60. Lazzi, S., Bellan, C., De Falco, G., Cinti, C., Ferrari, F., Nyongo, A., Claudio, P.P., Tosi, G.M., Vatti,R., Gloghini, A., Carbone, A, Giordano, A., Leoncini, L., Tosi, P. Expression of RB2/p130 tumor-suppressor gene in AIDS-related non-Hodgkin's lymphomas: Implications for disease pathogenesis.Human Pathol., 33, 7: 723-731, 2002.

61. Claudio, P.P., Tonini, T., Giordano, A. The retinoblastoma family: twins or distant cousins? GenomeBiol. 3: 9, REVIEWS3012, 2002.

62. Claudio PP, Giordano A. Preparation of retroviral vectors for cell-cycle-targeted gene therapy of lungcancer. Methods Mol Med 2003: 75: 591-605.

63. Pier Paolo Claudio, Candace, M. Howard A controlled trial of a human papillomavirus type 16vaccine. N Engl J Med 2002; 374:1645-51. Commentary, The Women’s Oncology Review, 3: 113-18-2003.

64. De Falco G., Bellan C., Lazzi S., Claudio P.P., La Sala D., Cinti C., Tosi P., Giordano A., Leoncini L.The interaction between HIV-1 Tat and pRb2/p130: a possible mechanism in the pathogenesis of AIDS-related neoplasms. Oncogene, 22; 6214-19, 2003

65. Tiziana Tonini, Francesca Rossi, Pier Paolo Claudio. Molecular basis of angiogenesis. Oncogene, 22:6549-56, 2003.

66. Russo G, Claudio PP, Fu Y, Stiegler P, Yu Z, Macaluso M and Giordano A. RB2/p130 target genes innon-small lung cancer identified by microarray analysis. Oncogene, 22; 6959-69, 2003.

67. Gaetano Romano, Pier Paolo Claudio, Tiziana Tonini, Antonio Giordano. Human immunodeficiencyvirus type 1 (HIV-1) derived vectors: safety considerations and controversy over therapeutic applications.The European J. of Dermatology, 13 (5): 424-9, 2003.

68. Claudio, P. P., Russo, G., Kumar, C. A., Minimo, C., Farina, A., Tutton, S., Nuzzo, G., Giuliante, F.,Angeloni, G., Maria, V., Vecchio, F. M., Campli, C. D., and Giordano, A. pRb2/p130, vascular endothelialgrowth factor, p27(KIP1), and proliferating cell nuclear antigen expression in hepatocellular carcinoma:their clinical significance. Clin Cancer Res, 10: 3509-3517, 2004.

69. Tonini, T., Claudio, P. P., Giordano, A., and Romano, G. Transient production of retroviral- andlentiviral-based vectors for the transduction of Mammalian cells. Methods Mol Biol, 285: 141-148, 2004.

70. Tonini, T., Claudio, P. P., Giordano, A., and Romano, G. Determination of Functional Viral Titer byDrug-Resistance Colony Assay, Expression of Green Fluorescent Protein, and beta-Galactoside Staining.Methods Mol Biol, 285: 149-154, 2004.

71. Tonini, T., Claudio, P. P., Giordano, A., and Romano, G. Retroviral and lentiviral vector titration bythe analysis of the activity of viral reverse transcriptase. Methods Mol Biol, 285: 155-158, 2004.

72. Tonini, T., Bagella, L., D'Andrilli, G., Claudio, P. P., and Giordano, A. Ezh2 reduces the ability ofHDAC1-dependent pRb2/p130 transcriptional repression of cyclin A. Oncogene, 23: 4930-4937, 2004.

73. Russo G, Giordano A, Claudio P.P. RBL2 (retinoblastoma-like 2). Atlas Genet Cytogenet OncolHaematol. March 2004. URL : http://www.infobiogen.fr/services/chromcancer/Genes/RBL2ID443.html

74. Vattemi E., Claudio P.P. Gene therapy for lung cancer: practice and promise. Ann Ital Chir. 2004May-Jun;75(3):279-89.

75. Giuseppe Russo, Alessandra Zamparelli, Candace M. Howard, Corrado Minimo, Cristiana Bellan,Giovanna Carrillo, Luigi Califano, Lorenzo Leoncini, Antonio Giordano, and Pier Paolo Claudio.Expression of Cell-Cycle Regulated Proteins pRB2/p130, p107, E2F4, p27, and of pCNA in SalivaryGland Tumors. Prognostic and diagnostic implications. Clinical Cancer Research, 2005 May1;11(9):3265-73.


76. Gilberto Sammartino, Mariano Tia, Gaetano Marenzi, A.E. di Lauro, Elio D’Agostino, and PierPaolo Claudio. Use of autologous platelet-rich plasma (PRP) in periodontal defect treatment afterextraction of impacted mandibular third molars. JOMS, Jun;63(6):766-70, 2005.

77. Francesco Papa, Antonio Cortese, Maria Cristina Maltarello, Raffaele Sagliocco, Pietro Felice, andPier Paolo Claudio. Outcome of 50 consecutive sinus lift operations. BJOMS, Aug;43(4):309-13, 2005.

78. Vattemi E., and Claudio P.P. Current status of gene therapy for lung cancer. Drugs of the Future 30:(10), 1017, 2005.

79. Giacinti L., Claudio P.P., Giordano A. Epigenetic Information and Estrogen Receptor AlfaExpression in Breast Cancer. The Oncologist, 2006 Jan;11(1):1-8.

80. Merola E. Claudio PP, Giordano A. p53 and the malignant progression of Barrett's esophagus. J CellPhysiol. Mar; 206(3):574-7, 2006.

81. Francesca Sanseverino, Rosa Santopietro, Michela Torricelli, Giuseppina D’Andrilli, GabrieleCevenini, Alessandro Bovicelli, Lorenzo Leoncini, Giovanni Scambia, Felice Petraglia, AntonioGiordano and Pier Paolo ClaudiopRb2/p130 and VEGF expressions in endometrial carcinoma in relationto angiogenesis and tumor histopathologic grade. Cancer Biol Ther. 2006 Jan 22;5(1).

82. Elettra Merola, Eliseo Mattioli, Corrado Minimo, Weineng Zuo, Carla Rabitti, Michele Cicala, RenatoCaviglia, Lucio Pollice, Antonio Giordano and Pier Paolo Claudio. Immunohistochemical evaluation ofpRb2/p130, VEGF, EZH2, p53, p16, p21waf-1, p27, and PCNA in Barrett’s Esophagus. Journal CellPhysiology, 207(2): 512-9, 2006.

83. Vogiatzi, P, De Falco G., Claudio PP, Giordano A. How Does the Human RUNX3 Gene InduceApoptosis in Gastric Cancer? Latest Data, Reflections and Reactions. Cancer Biol Ther. (4):371-374,2006.

84. Abbadessa G., Santoro A., and Claudio P.P. Meeting Report: 42nd Annual Meeting of the AmericanSociety of Clinical Oncology (ASCO) June 2-6, 2006, Atlanta, GA. Drugs of the Future 31:(7), 2006.

85. Pier Paolo Claudio, Chiara Mariano, Sujatha Radhakrishnan, Kamel Khalili, Mahmut Safak, AntonioGiordano, Shohreh Amini, and Bassel E Sawaya. Phosphorylation of p53 by cdk9 prevents HIV-1 genetranscription and viral replication. Journal Cell Physiology 208(3): 602-612, 2006.

86. Genovese C., Trani D., Caputi M., Claudio, P.P. Cell cycle control and beyond: emerging roles forthe retinoblastoma gene family. Oncogene. 2006 Aug 28;25(38):5201-9.

87. Vogiatzi, P., Abbadessa, G., Cassone, M., Claudio, P.P. The limitless role of p53 in cell cyclemachinery: good news or bad news? Cancer Biol Ther. 2006 Sep; 5(9):1090-3.

88. Vattemi M, and Claudio PP. Adenoviral gene therapy in head and neck cancer. Drug News Perspect.2006 Jul-Aug;19(6):329-37.

89. Howard, C.M., Forsberg F., Liu, J.B., Merton D.A., Minimo C., Pier Paolo Claudio Ultrasoundguided site specific gene delivery system using adenoviral vectors and commercial ultrasound contrastagents. Journal Cell Physiology 2006 Nov; 209 (2):413-21.

90. Paraskevi Vogiatzi, Marco Cassone, and Pier Paolo Claudio. On the road to personalizing genetherapy in gastric cancer: proposals for transforming dreams into reality. Drug News Perspect. 2006Nov;19(9):533-40.

91. Eliseo Mattioli, Paraskevi Vogiatzi, Ang Sun, Giovanni Abbadessa, Giulia Angeloni, DomenicoD’Ugo, Daniela Trani, John P. Gaughan, Fabio Maria Vecchio, Gabriele Cevenini, Roberto Persiani,Antonio Giordano, and Pier Paolo Claudio Immunohistochemical analysis of pRb2/p130, VEGF, EZH2,p53, p16 INK4A, p27KIP1, p21WAF1, Ki-67 expression patterns in gastric cancer. J Cell Physiol. 2007Jan; 210(1):183-91.

92. Bagella, Tiziana Tonini, Giuliano Cottone, Pier Paolo Claudio, Marco G. Paggi, Antonio De Luca,


Antonio Giordano. A small molecule based on the pRb2/p130 spacer domain leads to inhibition of cdk2activity and cell cycle arrest. Oncogene, 2007 Mar 22;26(13):1829-39

93. De Falco, G., Leucci, E., Lenze, D., Piccaluga, PP, Claudio, PP, Onnis, A., Cerino, G., Nyagol, J.,Mwanda, W., Bellan, C., Hummel, M., Pileri, S., Tosi, P., Stein, H., Giordano, A., Leoncini, L. Gene-expression analysis identifies novel RBL2/p130 target genes in endemic Burkitt's lymphoma cell linesand primary tumors. Blood. 2007 Aug 15;110(4):1301-7.

94. Giovanni Abbadessa, Paraskevi Vogiatzi, Lorenza Rimassa and Pier Paolo Claudio. Antiangiogenicdrugs currently used for colorectal cancer: what other pathways can we target to prolong responses? DrugNews and Perspectives, June 2007, 20 (5), 1-7.

95. Antonio Graziano, Vincenzo Desiderio, and Pier Paolo Claudio. Stem cells in tissue engineering fortherapeutic use, a promising tool or an approachable reality? Drugs Future 31(12): 1117, 2006.

96. Candace M. Howard and Pier Paolo Claudio Meeting report of the 2006 Radiological Society ofNorth America (RSNA). Molecular imaging: Novel techniques that not only visualize cellular changesdriving disease processes before they become apparent anatomically, but also useful therapeutic tools formultiple diseases? Drugs of the Future, 2007.

97. Emanuela Vattemi and Pier Paolo Claudio Advances and Perspectives of Gene- Based therapy forBrest Cancer. Drugs Fut 32(6): 507, 2007.

98. Emanuela Vattemi and Pier Paolo Claudio Tumor Suppresor Genes as Cancer Therapeutics DrugsNews Perspectives Oct;20(8):511-20, 2007.

99. Paraskevi Vogiatzi, Pierpaolo Aimola, Scarano M. Irene and Pier Paolo Claudio. Epigenome: fromthe control of cell growth to cancer. Drug News Perspectives Dec;20(10):627-33, 2007.

100. Gilberto Sammartino, Gaetano Marenzi, Candace Howard, Oreste Trosino, Corrado Minimo, LuigiCalifano, and Pier Paolo Claudio. Chondrosarcoma of the jaw: an anterior mandibular localization. Acase report with a four-year follow-up. Journal of Maxillofacial Surgery 2008 Nov;66(11):2349-55.

101. S. E. Kelly, Di Benedetto A., Valluri, J.V., Claudio, P.P. Selection and Proliferation of Stem Cells. Gravitational and Space Biology, 2008.

102. Manuela Vattemi and Pier Paolo Claudio. The feasibility of Gene Therapy in the Treatment ofHead and Neck Cancer. Head and Neck Oncology. Invited Review Article. Head Neck Oncol. 2009 Jan12;1(1):3.

103. Manuela Vattemi and Pier Paolo Claudio. CONTUSUGENE LADENOVEC. Monograph, Drugsof the Future 2009, 34(3):1-6.

104. Adelaide Greco, Altomare DiBenedetto, Candace Howard, Sarah Kelly, Yulia Dementieva, MicheleMiranda, Arturo Brunetti, Marco Salvatore, Luigi Claudio, Devanand Sarkar, Paul B. Fisher, and PierPaolo Claudio. Eradication of therapy-resistant human prostate tumors using an ultrasound guided site-specific Mda7/IL-24 cancer terminator virus. Molecular Therapy (in press, 2009).

105. Gilberto Sammartino, Mariano Tia, Gaetano Marenzi, Eva Gentile, and Pier Paolo Claudio. CouldPRP and resorbable membrane be considered an effective solution in the prevention of periodontal defectsfollowing deep impacted lower third molar extraction? Journal of Maxillofacial Surgery. (in press, 2009).

106. Paraskevi Vogiatzi, Marco Cassone, Luigi Claudio, and Pier Paolo Claudio Targeted Therapy forHormone-Refractory Prostate Cancer: Looking Through New Lenses. Drugs News and Perspectives (inpress, 2009).

107. Vincenzo Desiderio, Antonio Graziano, Pierpaolo Aimola and Pier Paolo Claudio. Stem cells incancer therapy: from their role into pathogenesis to their use as therapeutic agents Drugs News andPerspectives (in press, 2009).


BOOK CHAPTERS:

1. De Luca A., Baldi A., Claudio P.P., Howard C.M., Campisi S., Giordano A., Condorelli G. (1995):The retinoblastoma gene and its role in cancer and differentiation. In Future Trends in Endocrinology.Ares-Serono Symposia Series-Frontiers in Endocrinology 14: 197-206.2. Howard C.M., Claudio P.P., Carbone M., Giordano A. (1998): SV40 and Human Cancer. in Samuels,S.W. and Upton, A.C. Genes, Cancer and Ethics In the Work Environment. OEM Press, Beverly, MA.167-174.3. Claudio P. P., Giordano A. (2000): RB1 and RB2. In Pass H.I., Mitchell J.B., Johnson D.H., TurrisiA.T., Minna J.D. (Ed.) Lung Cancer: Principles and Practice. Lippincot Williams & Wilkins. 7: 133-1554. Claudio PP, Giordano A. (2003): Preparation of retroviral vectors for cell cycle-targeted gene therapyof lung cancer. In Barbara Driscoll (Ed.) Lung Cancer, volume II, Diagnostic and therapeutic methods andreviews. Methods Mol Med. Humana Press. 75: 591-605.5. Montella, M., Gallipoli, A., Lorusso, A., Creazzola, S., Claudio, P.P., D’Errico, G. (2003):L’organizzazione della lotta contro i tumori. Capitolo 36. In Mazzeo, F., Forestieri, P. Ed. Piccin NuovaLibraria Padova. Trattato di Chirurgia Oncologica. Vol 1, pag. 36.1-36.23.6. Claudio, F., Claudio, P.P. (2003): I tumori della lingua. Capitolo 36. In Mazzeo, F., Forestieri, P. Ed.Piccin Nuova Libraria Padova. Trattato di Chirurgia Oncologica. Vol 2, pag. 39.1-39.42.7. Tiziana Tonini, Pier Paolo Claudio, Antonio Giordano and Gaetano Romano. (2004): in Methods inMolecular Biology. Cell cycle control and dysregulation protocols. Part IV RETROVIRIDAE-BASEDVECTORS: PROTOCOLS FOR LENTIVIRAL – AND RETROVIRAL-MEDIATED GENETRANSFER TO ENGINEER CELL CULTURE SYSTEMS. Transient production of retroviral-andlentiviral-based vectors for the transduction of mammalian cells. Humana Press, Chapter 18.8. Tiziana Tonini, Pier Paolo Claudio, Antonio Giordano and Gaetano Romano. (2004): in Methods inMolecular Biology. Cell cycle control and dysregulation protocols. Part IV RETROVIRIDAE-BASEDVECTORS: PROTOCOLS FOR LENTIVIRAL – AND RETROVIRAL-MEDIATED GENETRANSFER TO ENGINEER CELL CULTURE SYSTEMS. Determination of functional viral titer bydrug-resistance colony assay, expression, expression of green fluorescent protein, and beta-galactosidasestaining. Humana Press, Chapter 19.9. Tiziana Tonini, Pier Paolo Claudio, Antonio Giordano and Gaetano Romano. (2004): in Methods inMolecular Biology. Cell cycle control and dysregulation protocols. Part IV RETROVIRIDAE-BASEDVECTORS: PROTOCOLS FOR LENTIVIRAL – AND RETROVIRAL-MEDIATED GENETRANSFER TO ENGINEER CELL CULTURE SYSTEMS. Retroviral and lentiviral vector titration bythe analysis of the activity of viral reverse transcriptase. Humana Press. Chapter 20.10. Pier Paolo Claudio, Antonio Giordano. Angiogenesis and cancer. Practical Medical Oncology . EdM. Lopez. Second Edition 2005.11. Molecular Pathology of Gynecological Cancer. Part VII: The multidisciplinary therapeutic approachto gynecological cancer in the new millennium. Chapter 13: The Holistic Approach to Female CancerPatients. Alessandro Bovicelli, Pier Paolo Claudio and Antonio Giordano. Humana Press.12. Claudio P.P. and Denning D. (2007): Nasopharyngeal carcinoma. In Cancer Research, anencyclopedic reference book. Springer Ed. 615-618.13. Claudio P.P. and Vogiatzi P. Regulation of cell cycle by retinoblastoma tumor suppressors. In:Signal Transduction: Pathways, Mechanisms and Diseases. Springer Ed. (2009, in press).

BOOKS:1. Claudio P.P., Savastano G. (1992): I tumori cutanei della faccia. Plastiche ricostruttive dopo exeresi.(Cutaneous tumors of the face. Reconstructive surgery after ablation) Ed. Scientifiche Italiane. Napoli, 1 -160.2. Califano L., Claudio P.P. (1995): I tumori della parotide. (Parotid tumors) Ed. Scientifiche Italiane.Napoli, 1-148.

Documents

Transportation Systems: The Outlook for Reauthorization of the